Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells 1,930 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Andrew Callos sold 1,930 shares of the business’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $62.07, for a total value of $119,795.10. Following the transaction, the executive vice president owned 78,185 shares of the company’s stock, valued at approximately $4,852,942.95. This trade represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Andrew Callos also recently made the following trade(s):

• On Tuesday, March 17th, Andrew Callos sold 8,542 shares of Cytokinetics stock. The stock was sold at an average price of $62.15, for a total transaction of $530,885.30.
• On Monday, March 16th, Andrew Callos sold 1,709 shares of Cytokinetics stock. The shares were sold at an average price of $61.03, for a total transaction of $104,300.27.
• On Monday, March 9th, Andrew Callos sold 2,582 shares of Cytokinetics stock. The stock was sold at an average price of $60.72, for a total transaction of $156,779.04.
• On Thursday, March 5th, Andrew Callos sold 26,000 shares of Cytokinetics stock. The shares were sold at an average price of $61.87, for a total transaction of $1,608,620.00.
• On Thursday, February 5th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The shares were sold at an average price of $61.93, for a total transaction of $928,950.00.
• On Monday, February 2nd, Andrew Callos sold 886 shares of Cytokinetics stock. The stock was sold at an average price of $62.10, for a total transaction of $55,020.60.
• On Monday, January 5th, Andrew Callos sold 15,000 shares of Cytokinetics stock. The stock was sold at an average price of $60.28, for a total value of $904,200.00.
• On Friday, January 2nd, Andrew Callos sold 1,798 shares of Cytokinetics stock. The shares were sold at an average price of $62.62, for a total value of $112,590.76.
• On Monday, December 29th, Andrew Callos sold 1,809 shares of Cytokinetics stock. The stock was sold at an average price of $62.44, for a total value of $112,953.96.

Cytokinetics Price Performance

Shares of NASDAQ:CYTK traded up $0.06 during trading on Wednesday, hitting $62.19. 1,983,803 shares of the company’s stock were exchanged, compared to its average volume of 1,895,650. The business’s 50-day simple moving average is $63.86 and its 200 day simple moving average is $60.93. The company has a market cap of $7.66 billion, a price-to-earnings ratio of -9.52 and a beta of 0.56. Cytokinetics, Incorporated has a 52-week low of $29.31 and a 52-week high of $70.98.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The business had revenue of $17.76 million during the quarter, compared to analyst estimates of $8.02 million. During the same period last year, the firm earned ($1.26) EPS. Cytokinetics’s revenue for the quarter was up 4.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Cytokinetics, Incorporated will post -5.24 EPS for the current fiscal year.

Trending Headlines about Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Mizuho raised its price target on CYTK to $100 and kept an outperform rating, signaling strong upside versus the current price and supporting bullish investor expectations. Mizuho raises PT to $100
• Positive Sentiment: JPMorgan nudged its target up from $74 to $75 and maintains an overweight/positive stance, reinforcing the buy-side view. JPMorgan raises PT to $75
• Positive Sentiment: Barclays reiterated a Buy rating on CYTK, adding to a broad base of favorable analyst coverage and a consensus price-target materially above the current level. Barclays keeps Buy rating
• Neutral Sentiment: Cytokinetics granted options (8,628 shares) and 5,719 RSUs as inducements to five new hires — standard hiring compensation but modestly dilutive over time. Inducement grants announcement
• Neutral Sentiment: Coverage and valuation pieces (including assessments after MYQORZO trial data) keep attention on the drug pipeline; results and safety updates will remain key catalysts. MYQORZO valuation assessment
• Negative Sentiment: Significant insider selling: CEO Robert Blum sold 36,601 shares (~$2.27M at ~\$62.15). Large insider disposals can signal liquidity needs or rebalancing and may pressure sentiment. CEO Form 4
• Negative Sentiment: Other senior executives sold notable blocks this week (EVP Fady I. Malik: 12,033 shares; EVP Andrew Callos: multiple sales including 1,930 and earlier lots; EVP Sung Lee: 4,935 shares), representing single-digit percentage ownership reductions—adds to selling narrative. EVP Form 4s

Institutional Trading of Cytokinetics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Lisanti Capital Growth LLC purchased a new stake in shares of Cytokinetics in the third quarter worth approximately $2,697,000. Sanders Morris Harris LLC purchased a new position in Cytokinetics during the 3rd quarter valued at $1,182,000. Y Intercept Hong Kong Ltd purchased a new position in Cytokinetics during the 3rd quarter valued at $1,359,000. Moody Aldrich Partners LLC bought a new position in Cytokinetics in the 3rd quarter valued at $4,532,000. Finally, Norges Bank bought a new position in Cytokinetics in the 2nd quarter valued at $39,122,000.

Wall Street Analyst Weigh In

Several research firms recently weighed in on CYTK. Mizuho raised their target price on shares of Cytokinetics from $84.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday. JPMorgan Chase & Co. increased their price objective on shares of Cytokinetics from $74.00 to $75.00 and gave the company an “overweight” rating in a report on Tuesday. B. Riley Financial raised their price objective on Cytokinetics from $90.00 to $108.00 and gave the company a “buy” rating in a research report on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cytokinetics in a report on Wednesday, January 21st. Finally, Robert W. Baird set a $84.00 price target on Cytokinetics in a research note on Tuesday, March 10th. Seventeen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Cytokinetics presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.89.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.